Mylan Inc (NASDAQ:MYL)

CAPS Rating: 4 out of 5

The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.

Recs

3
Player Avatar RXDOC73 (99.24) Submitted: 10/28/2008 3:44:35 PM : Outperform Start Price: $11.00 MYL Score: +265.21

The population is just getting older and more people are going to need more drugs. There is a great deal of consolidation in the field and only the strong companies like this one will survive the fallout.

Also a great takeover target for the likes of TEVA.

Member Avatar jimgggg1 (< 20) Submitted: 9/30/2009 11:15:29 AM
Recs: 0

New FDA approval

PITTSBURGH, Sept. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.

Featured Broker Partners


Advertisement